Batrozyme has a role in sudden deafness. The physiopathological mechanism of sudden deafness is not yet fully understood, and the currently recognized pathogenesis includes inner ear vasospasm, vascular striatal dysfunction, vascular embolism or thrombosis, and labyrinthine effusion. Batroxidase can reduce the level of fibrinogen in the blood, inhibit angiogenesis, dissolve thrombus, and improve blood circulation. It is effective for sudden deafness caused by inner ear vasospasm, vascular striae dysfunction, vascular embolism or thrombosis. Current guidelines recommend glucocorticoids as the initial treatment for sudden deafness, based on a combination of drugs to improve inner ear circulation, such as ginaldo and bactrim. Batroxidase has a fibrinogen-lowering effect, and blood fibrinogen concentrations need to be monitored when the drug is used, and are usually not less than 800 mg/dl before use. There may be bleeding or prolonged bleeding time after using the drug. For people with bleeding, recent surgery, in abdominal pain with anticoagulant effect and inhibit platelet function drugs, such as aspirin, warfarin, etc., bactrim is prohibited. Sudden deafness need to go to the regular hospital, specialist standardized treatment.